These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 12803929)

  • 1. Substrate reduction therapy: clinical evaluation in type 1 Gaucher disease.
    Moyses C
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):955-60. PubMed ID: 12803929
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Substrate reduction therapy of glycosphingolipid storage disorders.
    Aerts JM; Hollak CE; Boot RG; Groener JE; Maas M
    J Inherit Metab Dis; 2006; 29(2-3):449-56. PubMed ID: 16763917
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Guidance on the use of miglustat for treating patients with type 1 Gaucher disease.
    Weinreb NJ; Barranger JA; Charrow J; Grabowski GA; Mankin HJ; Mistry P
    Am J Hematol; 2005 Nov; 80(3):223-9. PubMed ID: 16247743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Miglustat: substrate reduction therapy for glycosphingolipid lysosomal storage disorders.
    Lachmann RH
    Drugs Today (Barc); 2006 Jan; 42(1):29-38. PubMed ID: 16511609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. An open-label, noncomparative study of miglustat in type I Gaucher disease: efficacy and tolerability over 24 months of treatment.
    Pastores GM; Barnett NL; Kolodny EH
    Clin Ther; 2005 Aug; 27(8):1215-27. PubMed ID: 16199246
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gaucher disease and the clinical experience with substrate reduction therapy.
    Zimran A; Elstein D
    Philos Trans R Soc Lond B Biol Sci; 2003 May; 358(1433):961-6. PubMed ID: 12803930
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effect of miglustat on bone disease in adults with type 1 Gaucher disease: a pooled analysis of three multinational, open-label studies.
    Pastores GM; Elstein D; Hrebícek M; Zimran A
    Clin Ther; 2007 Aug; 29(8):1645-54. PubMed ID: 17919546
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Switching from imiglucerase to miglustat for the treatment of French patients with Gaucher disease type 1: a case series.
    Serratrice C; Swiader L; Serratrice J
    J Med Case Rep; 2015 Jun; 9():146. PubMed ID: 26100396
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enzyme replacement and substrate reduction therapy for Gaucher disease.
    Shemesh E; Deroma L; Bembi B; Deegan P; Hollak C; Weinreb NJ; Cox TM
    Cochrane Database Syst Rev; 2015 Mar; 2015(3):CD010324. PubMed ID: 25812601
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Biochemical response to substrate reduction therapy versus enzyme replacement therapy in Gaucher disease type 1 patients.
    Smid BE; Ferraz MJ; Verhoek M; Mirzaian M; Wisse P; Overkleeft HS; Hollak CE; Aerts JM
    Orphanet J Rare Dis; 2016 Mar; 11():28. PubMed ID: 27008851
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patients with Gaucher type 1: Switching from imiglucerase to miglustat therapy.
    Canda E; Kose M; Kagnici M; Ucar SK; Sozmen EY; Coker M
    Blood Cells Mol Dis; 2018 Feb; 68():180-184. PubMed ID: 28111116
    [No Abstract]   [Full Text] [Related]  

  • 12. Gaucher disease and its treatment options.
    Bennett LL; Mohan D
    Ann Pharmacother; 2013 Sep; 47(9):1182-93. PubMed ID: 24259734
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful switch from enzyme replacement therapy to miglustat in an adult patient with type 1 Gaucher disease: a case report.
    Giuffrida G; Lombardo R; Di Francesco E; Parrinello L; Di Raimondo F; Fiumara A
    J Med Case Rep; 2016 Nov; 10(1):315. PubMed ID: 27821156
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Combination therapy in a patient with chronic neuronopathic Gaucher disease: a case report.
    Ceravolo F; Grisolia M; Sestito S; Falvo F; Moricca MT; Concolino D
    J Med Case Rep; 2017 Jan; 11(1):19. PubMed ID: 28103924
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gaucher disease: unmet treatment needs.
    Mehta A
    Acta Paediatr; 2008 Apr; 97(457):83-7. PubMed ID: 18339195
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Gaucher disease: hematologic and oncologic implications.
    Hughes D
    Clin Adv Hematol Oncol; 2011 Oct; 9(10):771-2. PubMed ID: 22252578
    [No Abstract]   [Full Text] [Related]  

  • 17. Novel oral treatment of Gaucher's disease with N-butyldeoxynojirimycin (OGT 918) to decrease substrate biosynthesis.
    Cox T; Lachmann R; Hollak C; Aerts J; van Weely S; Hrebícek M; Platt F; Butters T; Dwek R; Moyses C; Gow I; Elstein D; Zimran A
    Lancet; 2000 Apr; 355(9214):1481-5. PubMed ID: 10801168
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Changes of bone metabolism in seven patients with Gaucher disease treated consecutively with imiglucerase and miglustat.
    Mikosch P; Reed M; Baker R; Holloway B; Berger L; Mehta AB; Hughes DA
    Calcif Tissue Int; 2008 Jul; 83(1):43-54. PubMed ID: 18553043
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Miglustat.
    McCormack PL; Goa KL
    Drugs; 2003; 63(22):2427-34; discussion 2435-6. PubMed ID: 14609352
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sustained therapeutic effects of oral miglustat (Zavesca, N-butyldeoxynojirimycin, OGT 918) in type I Gaucher disease.
    Elstein D; Hollak C; Aerts JM; van Weely S; Maas M; Cox TM; Lachmann RH; Hrebicek M; Platt FM; Butters TD; Dwek RA; Zimran A
    J Inherit Metab Dis; 2004; 27(6):757-66. PubMed ID: 15505381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.